PMC:7288617 / 3341-3550 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T22","span":{"begin":100,"end":114},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"b, and anti-GQ1b, was negative.\nBased on the clinical presentation and CFS findings, an intravenous immunoglobulin (IVIG) therapy was initiated at 0.4 g/kg for 5 days. The neurological symptoms resolved 7 days"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T36","span":{"begin":71,"end":74},"obj":"Disease"}],"attributes":[{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005404"}],"text":"b, and anti-GQ1b, was negative.\nBased on the clinical presentation and CFS findings, an intravenous immunoglobulin (IVIG) therapy was initiated at 0.4 g/kg for 5 days. The neurological symptoms resolved 7 days"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T23","span":{"begin":12,"end":16},"obj":"Chemical"}],"attributes":[{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_27515"}],"text":"b, and anti-GQ1b, was negative.\nBased on the clinical presentation and CFS findings, an intravenous immunoglobulin (IVIG) therapy was initiated at 0.4 g/kg for 5 days. The neurological symptoms resolved 7 days"}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T7","span":{"begin":12,"end":16},"obj":"GlycoEpitope"}],"attributes":[{"id":"A7","pred":"glyco_epitope_db_id","subj":"T7","obj":"http://www.glycoepitope.jp/epitopes/EP0069"}],"text":"b, and anti-GQ1b, was negative.\nBased on the clinical presentation and CFS findings, an intravenous immunoglobulin (IVIG) therapy was initiated at 0.4 g/kg for 5 days. The neurological symptoms resolved 7 days"}

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":32,"end":167},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"b, and anti-GQ1b, was negative.\nBased on the clinical presentation and CFS findings, an intravenous immunoglobulin (IVIG) therapy was initiated at 0.4 g/kg for 5 days. The neurological symptoms resolved 7 days"}